What the CU Anschutz Semaglutide Trial Found

Oral semaglutide — the same medication sold as Ozempic and Wegovy for diabetes and weight loss — reduced heavy drinking in a small clinical trial led by researchers at the University of Colorado Anschutz Medical Campus. In 50 adults with moderate-to-severe alcohol use disorder, the drug was associated with fewer heavy drinking days, less alcohol consumed per occasion, weaker daily cravings and fewer alcohol-related problems.

The researchers deliberately studied the pill form of semaglutide because injectable versions had shown similar effects in earlier research, but a pill was expected to be more acceptable to patients. The oral drug was generally well tolerated, with mostly mild side effects and high adherence, according to the university. Participants taking semaglutide also reported using less cannabis during the study.

The finding carries extra weight because alcohol use disorder has not had a new FDA-approved medication since 2006. Only three drugs are approved for the condition, even though an estimated 27.9 million Americans aged 12 and older experienced alcohol use disorder in the past year, according to 2024 data from the National Survey on Drug Use and Health. Dr. Joseph Schnacht of the CU Anschutz team said semaglutide “could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications.”

CU Anschutz and researchers at other institutions now plan larger, longer-term trials to confirm the results and establish the right dose for alcohol use disorder. Any path to FDA approval would follow those studies, not this single early-stage trial.

Advertisement

Why the Semaglutide Trial Matters for Alcohol Use Disorder Treatment

The Treatment Gap Semaglutide Could Fill

Alcohol use disorder is common and chronically undertreated. The FDA has approved only three medications for it, the newest of which dates back to 2006, while an estimated 27.9 million Americans experienced the condition in the past year. Against that backdrop, a trial showing reductions in heavy drinking days, consumption per occasion, cravings and alcohol-related problems is a meaningful clinical signal — even though the study is small and the press summary does not report the size of the effect in detail.

Why the Pill Version Could Matter for Adoption

The CU Anschutz team chose oral semaglutide rather than the injectable forms of the drug. Earlier research on injectables pointed in the same direction, but the researchers reasoned that a pill would be easier for this patient population to accept. If that acceptability translates into adherence in larger trials, the formulation could determine whether semaglutide becomes a widely used alcohol use disorder treatment or remains an academic curiosity.

What This Could Mean for Semaglutide's Commercial Run

Semaglutide — sold as Ozempic and Wegovy by Novo Nordisk, though the drugmaker is not named in the university's release — is already a major commercial product in diabetes and obesity. A confirmed alcohol use disorder indication would extend it into a third, undertreated patient population and give the drug a new revenue line as the GLP-1 category becomes more crowded. Interpretation: this is an investable clinical signal, not a regulatory milestone; the commercial outcome depends on the planned larger trials and any FDA submission that follows.

What Needs to Happen Next

The headline result is early. The study enrolled 50 patients at a single institution, efficacy was measured through patient-reported outcomes, and the optimal dose for alcohol use disorder has not been established. The next milestones are replication in larger, longer-term trials, followed by regulatory review. Each of those steps carries real uncertainty.

Next Steps for Patients, Clinicians and Semaglutide's Commercial Future

  • Patients: Semaglutide is not approved for alcohol use disorder, and the trial's 50-patient size plus unconfirmed dosing mean this study does not support self-medicating with Ozempic or Wegovy for drinking problems. The three FDA-approved medications for alcohol use disorder remain the established options to discuss with a doctor.
  • Clinicians: Treat the CU Anschutz results as an early signal rather than a reason to change prescribing. The next meaningful development is the planned larger, longer-term trials, not a new indication.
  • Investors: The commercial read-through is real but conditional: a confirmed indication would open semaglutide to a population of 27.9 million affected Americans. The realistic near-term catalysts to track are trial registrations or a formal FDA filing from the drug's manufacturer, with approval still several years away.

Risk & Opportunity Assessment

Commercial RiskMediumSemaglutide's core diabetes and obesity franchises are not threatened by this trial, but failure in confirmatory studies would eliminate a promising AUD revenue option; existing AUD treatments are older generics.
Competitive RiskMediumIf confirmed, semaglutide would enter an undertreated market with only three older FDA-approved medications, and its oral form could become the most patient-friendly option; rival GLP-1 and addiction-therapy developers could respond.
Regulatory RiskMediumFDA approval for alcohol use disorder would require larger, longer-term efficacy and safety data; the 50-patient study is too small to support a submission, and off-label use pressure could increase scrutiny.
Reputation RiskLowA positive university-run trial generally strengthens the drug's profile; reputational damage would only materialize if results fail to replicate or off-label use leads to safety incidents.
Technology DisruptionLowSemaglutide is an established GLP-1 molecule; the study adds a potential use case rather than introducing a new technology platform.
Commercial OpportunityHighA confirmed indication could serve an affected U.S. population of 27.9 million, add a third revenue stream for semaglutide, and deliver the first new alcohol use disorder medication since 2006.